Xilis MicroOrganoSphere
Precision oncology platform using miniature patient replicas.
Uses patient biopsies and AI-driven analysis of miniature organ replicas (MOS) to assess reactions to diverse drugs, enabling the optimal personalized treatment path for cancer.
PROS
- + Provides functional evidence of drug response
- + bridging the gap between genomic data and treatment efficacy.
- + Rapid turnaround time (around 10-14 days) enables timely clinical decision-making.
- + Replicates the tumor microenvironment
- + including immune and stromal cells
- + for higher fidelity testing.
- + Automated and scalable process for high-throughput
- + reproducible drug response profiling.
CONS
- - Relies on the availability and processing of a patient tissue biopsy sample.
- - A specialized B2B service
- - requiring partnership or service contract access.
- - Cost per patient assay
- - though positioned as cost-effective
- - may be substantial.
-
Guiding initial therapy selection for cancer patients with functional drug testing
-
Identifying and testing secondary treatment options for patients with drug-resistant or relapsed cancer
-
Accelerating preclinical drug efficacy and toxicity testing in pharmaceutical R&D
-
Providing functional confirmation to increase clinician confidence in treatment decisions
SIMILAR TOOLS
Claude Healthcare
Claude helps healthcare organizations move faster without sacrificing accuracy, safety, or compliance. Less administrative work, more time with the people you serve.
ChatGPT Health
A dedicated experience in ChatGPT designed for health and wellness.
Verily
Precision health platform for research and patient care.
Medtronic (AI Surgery & Diabetes)
AI integrated into surgical robotics and chronic disease.